Literature DB >> 33410494

Tocilizumab for refractory rapidly progressive interstitial lung disease related to anti-MDA5-positive dermatomyositis.

Xiao Zhang1, Shuang Zhou1, Chanyuan Wu1, Mengtao Li1, Qian Wang1, Yan Zhao1, Xiaofeng Zeng1.   

Abstract

Entities:  

Year:  2021        PMID： 33410494     DOI： 10.1093/rheumatology/keaa906

Source DB:  PubMed          Journal:  Rheumatology (Oxford)        ISSN： 1462-0324            Impact factor:   7.580


× No keyword cloud information.
  4 in total

Review 1.  Myositis-associated interstitial lung disease: a comprehensive approach to diagnosis and management.

Authors:  Robert W Hallowell; Julie J Paik
Journal:  Clin Exp Rheumatol       Date:  2021-03-25       Impact factor: 4.473

Review 2.  COVID-19 Disease and Dermatomyositis: A Mini-Review.

Authors:  Jie Qian; Hui Xu
Journal:  Front Immunol       Date:  2022-01-13       Impact factor: 7.561

3.  Risk Factors and Predictive Model for Dermatomyositis Associated with Rapidly Progressive Interstitial Lung Disease.

Authors:  Kai Wang; Yian Tian; Shanshan Liu; Zhongyuan Zhang; Leilei Shen; Deqian Meng; Ju Li
Journal:  Pharmgenomics Pers Med       Date:  2022-09-01

4.  Promising Neutrophil-Associated Biomarkers in Lung Diseases of Patients with Antisynthetase Syndrome and Dermatomyositis.

Authors:  Lei Liu; Jundi Wang; Peiyu Zhang; Wenjia Sun; Xiuliang Zhu; Xiujuan Sun; Jing Xue; Huaxiang Wu
Journal:  J Immunol Res       Date:  2022-09-26       Impact factor: 4.493
  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.